Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, ...
Mar 21, 2013
0
0
(HealthDay)—An experimental therapy that targets the immune system might offer a new way to treat an often deadly form of adult leukemia, a preliminary study suggests.
Mar 20, 2013
0
0
Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia ...
Feb 26, 2013
0
0
British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.
Feb 13, 2013
0
0
Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible ...
Feb 11, 2013
0
0
After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer—the first time anyone has linked ...
Feb 3, 2013
0
0
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...
Jan 25, 2013
0
0
(Medical Xpress)—An international team of researchers has developed a new anti-cancer drug that holds promise as a therapy that fights cancer while causing fewer side effects than current medicines. The work done by the ...
The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved ...
Dec 21, 2012
0
0
(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..
Dec 16, 2012
0
0
